[Urotensin II promotes atherosclerosis].
Watanabe
Takuya
T
Department of Biochemistry, Showa University School of Medicine, Tokyo, Japan.
D000634:Aminoquinolines; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000209:etiology*; D018955:CD36 Antigens / Q000378:metabolism; D015195:Drug Design; D005487:Foam Cells; D006801:Humans; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D002785:Sterol O-Acyltransferase / Q000378:metabolism; D014579:Urotensins / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D014661:Vasoconstriction
D000634:Aminoquinolines; D018955:CD36 Antigens; D008077:Lipoproteins, LDL; D017382:Reactive Oxygen Species; D043562:Receptors, G-Protein-Coupled; C121697:UTS2R protein, human; D014579:Urotensins; C099252:oxidized low density lipoprotein; C029677:urotensin II; D002785:Sterol O-Acyltransferase; C493492:sterol O-acyltransferase 1; C001920:4-aminoquinoline